作者:Ute F. Röhrig、Somi Reddy Majjigapu、Aline Reynaud、Florence Pojer、Nahzli Dilek、Patrick Reichenbach、Kelly Ascencao、Melita Irving、George Coukos、Pierre Vogel、Olivier Michielin、Vincent Zoete
DOI:10.1021/acs.jmedchem.0c01968
日期:2021.2.25
heme enzyme indoleamine 2,3-dioxygenase 1 (IDO1) plays an essential role in immunity, neuronal function, and aging through catalysis of the rate-limiting step in the kynurenine pathway of tryptophan metabolism. Many IDO1 inhibitors with different chemotypes have been developed, mainly targeted for use in anti-cancer immunotherapy. Lead optimization of direct heme iron-binding inhibitors has proven difficult
血红素酶吲哚胺 2,3-双加氧酶 1 (IDO1) 通过催化色氨酸代谢犬尿氨酸途径中的限速步骤在免疫、神经元功能和衰老中发挥重要作用。已经开发了许多具有不同化学型的 IDO1 抑制剂,主要用于抗癌免疫治疗。由于血红素-配体相互作用的显着选择性和敏感性,直接血红素铁结合抑制剂的先导优化已被证明是困难的。在这里,我们提供了一组密切相关的小唑类化合物的实验数据,它们的抑制活性存在超过 4 个数量级的差异,范围从毫摩尔到纳摩尔水平。我们根据结构数据、分子动力学模拟和密度泛函理论计算来调查和合理化它们的活动。